Over recent years, several biomarkers as predictors of immunotherapeutic efficacy have been studied, the most important being CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs), PD-L1 expression on tumor cells, tumor mutational burden (TMB) and microsatellite instability (MSI). The gene discussed is CD8A; the disease is neoplasm.